Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Liabilities and Shareholders Equity (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 21.49% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $3.8 billion, up 6.79%, while the annual FY2025 figure was $1.1 billion, 21.49% up from the prior year.
  • Liabilities and Shareholders Equity reached $1.1 billion in Q4 2025 per APLS's latest filing, up from $1.1 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q1 2022 and bottomed at $525.7 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $874.3 million, with a median of $877.3 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 31.58% in 2021, then soared 66.05% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $881.8 million in 2021, then decreased by 13.78% to $760.2 million in 2022, then increased by 3.75% to $788.7 million in 2023, then grew by 12.21% to $885.1 million in 2024, then rose by 21.49% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $821.4 million in Q2 2025.